Olivier Godement, the head of product for OpenAI's developer platform, said companies should secure top-down buy-in when ...

Imagine you are developing antibodies—drugs precisely aimed at a target, for example a viral protein or onco-marker. You test a series of antibodies and find that some work, while others do not.